Gilead Sciences Fund Examining Long-Term Effects of COVID-19 and Effectiveness of Remdesivir Drug

Gilead Sciences Fund Examining Long-Term Effects of COVID-19 and Effectiveness of Remdesivir Drug

Monday, 13 July, 2020

Gilead Sciences, Inc is a research-based biopharmaceutical company focused on the discovery, development, and commercialisation of innovative medicines. The company has launched the 'COvid-19 unMet MedIcal needs and associated research extension' (COMMIT) programme to address the unmet medical need in coronavirus/COVID-19.

The programme will support individual projects with clear objectives, defined timelines, a comprehensive operational plan, and propose data that has relevance to the medical community. Gilead will consider support for research proposals that meet one of the following criteria:

  • Expand data on clinical course and outcome in vulnerable populations:
    • Immune suppressed, specifically- HIV, cancer chronic inflammatory conditions (ie RA or IBD), and chronic liver disease, pre-existing pulmonary disease.
    • Residents of long-term care facilities/nursing homes, and older adults.
    • At risk for healthcare disparities (eg BAME, socio-economic class).
  • Long-term sequelae (ie pulmonary fibrosis, neurologic, cardiac, quality of life).
  • Real world safety and effectiveness of remdesivir used alone or with other agents (JAK inhibitors, IL-6 inhibitors, convalescent plasma and ACE inhibitors and ARBs):
    • Viral kinetics and clinical outcomes.
    • Based on duration of treatment (eg five vs ten days, shorter courses).
    • Use in early (non-severe) disease.
    • Course completion in alternative (non-inpatient setting) or alternative treatment pathways.

Gilead will not consider proposals that request COVID-19 screening costs (including test kits) or proposals that requests remdesivir or other study drug.

This international opportunity is open to organisations including research institutes, government entities, and hospitals. Projects should last between six and nine months and have a value of up to $250,000 (inclusive of overhead costs and applicable taxes) or equivalent sum. Gilead approval will be required prior to submission for proposals with a budget of greater than this amount.

Interested applicants should download and complete the LOI form and ISR Overhead Policy form from the call webpage and return them by the 3 August 2020 deadline.

 

More information about this research funding opportunity and the application process is available on the RESEARCHconnect funding information platform. RESEARCHconnect provides up-to-the minute content, insight and analysis on research funding news and policy. To find out more about how RESEARCHconnect can keep you in the know, and subscription fees, contact us today.

 

other funding news

Our experienced content team is skilled at sourcing funding opportunities, reporting on the latest hot topics and providing accurate, comprehensive funding content which supports organisations and their beneficiaries in their quest for funding.

Interested in finding out more about
RESEARCHconnect and subscription fees?

RESEARCHconnect

Supporting you at every step of your funding journey